Sanofi (NASDAQ:SNY) Holdings Cut by Augustine Asset Management Inc.

Augustine Asset Management Inc. cut its stake in shares of Sanofi (NASDAQ:SNY) by 2.3% in the 4th quarter, Holdings Channel reports. The firm owned 81,075 shares of the company’s stock after selling 1,913 shares during the quarter. Sanofi comprises approximately 1.0% of Augustine Asset Management Inc.’s holdings, making the stock its 19th biggest position. Augustine Asset Management Inc.’s holdings in Sanofi were worth $3,910,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Savant Capital LLC grew its position in shares of Sanofi by 24.8% during the fourth quarter. Savant Capital LLC now owns 6,361 shares of the company’s stock worth $307,000 after acquiring an additional 1,264 shares during the last quarter. Apollon Wealth Management LLC grew its position in Sanofi by 8.8% in the 4th quarter. Apollon Wealth Management LLC now owns 17,865 shares of the company’s stock worth $862,000 after purchasing an additional 1,441 shares during the last quarter. Mezzasalma Advisors LLC increased its stake in shares of Sanofi by 24.0% in the fourth quarter. Mezzasalma Advisors LLC now owns 12,686 shares of the company’s stock valued at $612,000 after purchasing an additional 2,452 shares during the period. Strategic Financial Concepts LLC bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $667,000. Finally, Leo Wealth LLC raised its holdings in shares of Sanofi by 5.9% during the fourth quarter. Leo Wealth LLC now owns 26,669 shares of the company’s stock valued at $1,286,000 after buying an additional 1,487 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $53.90 on Wednesday. The firm has a market capitalization of $136.79 billion, a PE ratio of 21.65, a P/E/G ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company’s 50 day simple moving average is $49.94 and its 200 day simple moving average is $52.40.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.